Osimertinib success in locally advanced EGFR-mutated NSCLC

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients

Adagrasib improves on docetaxel in previously treated NSCLC

Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with NDMM: MRD analysis

Melanoma outcomes improved by dual immunotherapy before surgery rather than after

Addition of cabazitaxel to abiraterone/prednisone significantly prolonged PFS in extensive mCRPC following docetaxel

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer

Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma

Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple myeloma

Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC

Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy